Innovation And EfficacySGT-003 represents a leap forward in innovation with several advantages that have translated to impressive and unprecedented amounts of microdystrophin in the first 3 treated patients.
Market OpportunityThe safety concerns on Elevidys could facilitate faster patient enrollment in SGT-003 study and potentially accelerate its clinical development.
Safety ProfileSGT-003 shows no evidence of even mild liver toxicity, potentially attributable to a more muscle tropic vector, and arguably stronger efficacy metrics on muscle restoration.